SESSION TITLE: Pulmonary Vascular Disease I
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Current guidelines for treatment of pulmonary arterial hypertension (PAH) recommend intravenous prostacyclin as first-line therapy in patients with World Health Organization (WHO) functional class (FC) IV, or combination therapy for patients with FC III or any FC who do not respond to monotherapy. Recent research identified patients enrolled in the REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management) Registry who deteriorated to FC IV or died, reporting that intravenous prostacyclin and combination therapy were not consistently used in this cohort. We sought to investigate the reason for this, suspecting that the etiology was not due to poor compliance with guidelines, but rather due to other patient factors not in control of the prescribing provider.